IBJNews

Effective stats are new hurdle for U.S. drugmakers

Back to TopCommentsE-mailPrintBookmark and Share

WellPoint Inc.’s announcement of comparative-effectiveness research guidelines last week marks a new era for U.S. drugmakers.

The Indianapolis-based health insurer said it will use studies that compare the effectiveness of one drug against another as a complement to typical clinical-trial research that compares a drug against a placebo sugar pill.

Congress has also approved $4.1 billion in the past 15 months to fund comparative-effectiveness studies and a new agency that specializes in them. Now that private insurers like WellPoint are joining in, the United States could see a wave of head-to-head comparisons that have historically been rare in pharmaceuticals.

The goal of both the public and private initiatives is better health care at lower cost. WellPoint will use comparative-effectiveness research to help determine what percentage of the cost of a new drug it will pay for.

“Good comparative-effectiveness research study, along with clinical trial information and other peer-reviewed studies published in medical journals, can provide us the tools we need to help improve health outcomes and reduce costs for members of our affiliated health plans," Brian Sweet, WellPoint’s chief pharmacy officer, said in a statement.

Comparative-effectiveness research was a controversial topic during last year’s health reform debate, as many feared government and private health plans would use the information to intrude in the doctor-patient relationship.

But for pharmaceutical companies, it’s just the new reality, said Linda Heitzman, a life sciences consultant at Deloitte Consulting in Indianapolis.

“Just proving your product is better than nothing is not enough. You have to be able to demonstrate that your product is better than other products on the market,” she said, noting that the U.S. market is actually catching up to demands for comparative-effectiveness research already coming from government health plans in the United Kingdom and other European countries.

Heitzman said comparative-effectiveness research is both a challenge and an opportunity for drugmakers.

“Where comparative effectiveness hurts pharma companies is in broad-based treatments [such us cholesterol-fighters or blood pressure medicines]. Trying to have one more product in that market is a non-starter,” she said. “Companies are going to have to take a much riskier strategy.”

But drug companies can and are using blood and genetic testing to identify small groups of patients for which their drug is a big breakthrough in treatment. Proof of high effectiveness in a small group can get a drug market approval from regulators and favorable pricing from insurers like WellPoint.

Then, Heitzman said, drugmakers can build from there to get their drugs approved for more and more patients.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT